Core Viewpoint - The company has approved the use of raised funds to provide loans to its subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., for the implementation of a new drug research and development project, amounting to a maximum of RMB 110 million [1][2][10]. Summary of Relevant Sections Fundraising Overview - The company raised a net amount of RMB 590.20 million after deducting issuance costs of RMB 8.37 million, as approved by the China Securities Regulatory Commission [1][2]. - The funds were deposited into a designated account on June 15, 2023, and verified by an accounting firm [1]. Changes in Fund Usage - The company decided to reduce the budget for the "Anti-tumor Drug R&D Project" from RMB 169.20 million to RMB 43.26 million, reallocating the reduced amount of RMB 125.94 million to the "Drug R&D Center and Supporting Facilities Construction Project" [1][2]. - The remaining unused funds from the "Anti-tumor Drug R&D Project" and "Digital Platform Upgrade Project" totaling RMB 103.08 million will now be used for the new drug R&D project at the subsidiary [2][5]. Loan Details - The loan to the subsidiary will be provided in stages based on actual project needs, with a term of 5 years and an interest rate referencing the Loan Prime Rate (LPR) [1][2][10]. - The board of directors has authorized the chairman or designated agents to handle related matters and sign necessary documents [1][10]. Financial Status of the Subsidiary - As of March 31, 2025, the subsidiary had total assets of RMB 670.36 million and total liabilities of RMB 219.90 million, resulting in net assets of RMB 450.46 million [11]. - The subsidiary reported a total revenue of RMB 125.27 million for the first quarter of 2025, with a net loss of RMB 528.35 million for the same period [11]. Related Party Transactions - The loan constitutes a related party transaction, as the subsidiary is controlled by the company, and the terms are deemed fair and reasonable [8][9][10]. - The independent directors and supervisory board have approved the transaction, confirming it aligns with legal regulations and does not harm the interests of shareholders [14][15].

Fundraising Overview - The company raised a total of RMB 364.71 million through a private placement in 2021, with a net amount of RMB 362.46 million after deducting various fees [1][6][18] - In 2023, the company issued 8,415,450 shares at RMB 32.88 per share, raising RMB 276.70 million, with a net amount of RMB 266.45 million after fees [4][6][18] Fund Allocation and Usage - As of March 31, 2025, the company had RMB 362.06 million in its fundraising account, with RMB 19.34 million allocated for temporary working capital [2][3][5] - The company has used RMB 102.44 million for working capital and has a remaining balance of RMB 17.32 million from the 2021 fundraising [14][18] Project Updates - The probe station R&D and industrialization project has been delayed, with the expected completion date extended to December 31, 2025, and the budget reduced to RMB 210.27 million [8][9][10] - The company has decided to redirect RMB 50 million from the probe station project to the high-end smart manufacturing base project, which aims to enhance production capacity [8][9][10] Financial Performance - The probe station project has reported a cumulative loss of RMB 7.10 million as of March 31, 2025, falling short of the expected profit of RMB 44.68 million [14][19] - The company has not made any performance commitments for the acquisition of Changyi Technology, which is now fully owned [16][19] Idle Funds Management - The company has utilized idle funds for temporary working capital, with a total of RMB 69.92 million used as of March 31, 2025, and all funds returned to the special account within the stipulated time [18][19]

证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法 律法规及规范性文件的有关规定，广东众生药业股份有限公司（以下简称"公司"） 第八届董事会独立董事专门会议 2025 年第四次会议于 2025 年 6 月 24 日在公司 会议室以通讯方式召开。本次会议应出席独立董事 3 人，实际出席独立董事 3 人。 经全体独立董事推举，本次会议由独立董事牟小容女士召集并主持。全体独立董 事本着认真、负责的态度，对公司相关议案及事项进行了审议并发表审核意见如 下： 一、会议以 3 票同意，0 票反对，0 票弃权的表决结果，审议通过了《关于 使用募集资金向控股子公司提供借款实施募投项目暨关联交易的议案》。 公司独立董事一致认为：本次公司使用募集资金向控股子公司提供借款实施 募投项目暨关联交易的事项符合《上市公司募集资金监管规则》《深圳证券交易 所股票上市规则》《深圳证券交易所上市公司自律监管指引第1号——主板上市 公司规范运作》等法律法规、规范性文件的规定，有利于保障募投项目的顺利实 施，符合公司及公司控股子公司广东众生睿创生物科技有限公司的实际情况，不 存在变相改变募集资金用途或损害公司股东尤其是中小 ...

Group 1 - The core viewpoint of the article is that Hongsheng Huayuan Tower Group Co., Ltd. is using raised funds to increase capital in its subsidiaries to implement investment projects, which has been verified by Zhongyin International Securities Co., Ltd. as the sponsor for the company's IPO [1][8] - The total amount of funds raised through the IPO is approximately RMB 1.137 billion, with a net amount of approximately RMB 1.037 billion after deducting issuance costs [1][2] - The funds will be allocated to several projects, including the production of transmission towers, smart manufacturing upgrades, and working capital supplementation, with a total investment of RMB 103.407 million [2][4] Group 2 - The company plans to increase capital in its wholly-owned subsidiaries, including Zhejiang Shengda Tower Co., Ltd., Zhejiang Yuanli Jiangdong Tower Co., Ltd., and Jiangsu Zhengguang Electric Power Equipment Manufacturing Co., Ltd. [2][4] - The specific capital increase amounts are RMB 9,081.30 million for Zhejiang Shengda, RMB 2,589.80 million for Yuanli Jiangdong, and RMB 5,671.30 million for Jiangsu Zhengguang [4][6] - The purpose of this capital increase is to align with the company's strategic development plan, enhance competitiveness, and ensure the smooth implementation of the investment projects [6][7] Group 3 - The company has established a dedicated account for the raised funds and signed a supervision agreement with subsidiaries and banks to ensure efficient and compliant fund management [7][8] - The board of directors and the supervisory board have approved the use of raised funds for capital increases, fulfilling necessary legal procedures [8] - The sponsor has confirmed that the use of raised funds complies with relevant regulations and does not harm the interests of the company and its shareholders [8]

Core Viewpoint - The report details the fundraising activities and the utilization of proceeds by Ningxia Dongfang Tantalum Industry Co., Ltd, highlighting the total amount raised, the status of funds, and the actual investment projects undertaken with the raised capital [1][2]. Fundraising Details - The company raised a total of RMB 670,204,385.22 through the issuance of 59,281,818 shares at a price of RMB 11.38 per share, with the funds received on September 27, 2023 [1]. - As of March 31, 2025, the company had a remaining balance of RMB 149,907,012.98 from the raised funds, which constitutes 22.37% of the net amount raised [1][2]. Fund Utilization - The actual investment amount from the raised funds was RMB 521,263,566.21, resulting in a difference of RMB 14,894,080.00 compared to the committed investment amount of RMB 67,020,440.00 [1][2]. - The discrepancies in investment amounts are attributed to ongoing construction phases and cost optimization strategies [1][2]. Project Performance - The annual production line for 100 niobium superconducting cavities reached its intended operational status by December 2024, but as of March 31, 2025, it generated a cumulative benefit of RMB 707,300, which is below the promised benefit of RMB 1,381,800 by over 20% [2][3]. - The company has not experienced any changes in the investment projects funded by the previous fundraising efforts [1][2]. Comparison with Annual Reports - The actual use of funds aligns with the disclosures made in the company's periodic reports since 2023, confirming consistency in reporting [2].

Core Viewpoint - The company is planning to issue shares through a simplified procedure to specific investors, which may dilute immediate returns for existing shareholders, and has proposed measures to mitigate this impact [4][6][12]. Group 1: Share Issuance and Financial Impact - The company intends to issue up to 19,900 million yuan in shares, which will increase the total share capital from 90,085,520 shares to 117,111,176 shares [5]. - The projected net profit for 2025 under three scenarios shows a potential decrease in basic earnings per share from 0.94 yuan to as low as 0.75 yuan due to the dilution effect [5][6]. - The company has committed to measures to ensure that the dilution of immediate returns is addressed, including enhancing the management of raised funds and accelerating project implementation [10][12]. Group 2: Shareholder Return Planning - The company has developed a three-year dividend return plan for 2025-2027, focusing on providing stable and reasonable returns to shareholders [13][14]. - The dividend distribution policy emphasizes that cash dividends should not exceed the cumulative distributable profits and must consider the company's operational needs [14][15]. - The company aims to distribute at least 10% of the annual distributable profits as cash dividends, with higher percentages for mature stages without significant capital expenditures [16][17]. Group 3: Previous Fund Utilization - The company reported that all previous fundraising has been fully utilized, with a total of 31,913.03 million yuan raised for various projects, including the construction of a new manufacturing facility [21][22]. - The actual investment in previous projects was 28,625.02 million yuan, with no significant deviations from the planned investment amounts [21][22]. - The company has established a robust management system for fundraising, ensuring compliance with regulations and effective use of funds [20][21].

Core Viewpoint - The report details the fundraising activities and usage of funds by Suzhou Ruikeda Connection System Co., Ltd, highlighting the amounts raised, the allocation of funds, and adjustments made to investment projects due to various factors. Fundraising Overview - The company raised a total of RMB 405.54 million from its initial public offering (IPO) by issuing 27 million shares at RMB 15.02 per share, with a net amount of RMB 349.83 million after deducting issuance costs [1]. - In 2022, the company raised RMB 683 million by issuing 5.16 million shares at RMB 132.44 per share, resulting in a net amount of RMB 670.45 million after costs [2]. Fund Allocation and Usage - As of May 31, 2025, the total amount invested from the IPO funds was RMB 354.63 million, exceeding the net amount raised by RMB 4.79 million, primarily due to interest and investment income [2]. - The company has established a dedicated fund management system to ensure the proper use of raised funds, adhering to relevant regulations [3]. Fund Management Agreements - The company has signed tripartite supervision agreements with various banks and its underwriter, ensuring the establishment of special accounts for the management of raised funds [4][5]. Project Adjustments - Due to the actual net amount raised being lower than the planned investment amounts, the company adjusted the investment amounts for its projects, including the high-performance precision connector industrialization project and working capital supplementation [8][9]. - The high-performance precision connector project has faced delays due to external factors such as public health events and supply chain disruptions, leading to an extension of the project's completion date to December 2023 [10][11]. Financial Performance and Benefits - The high-performance precision connector project is expected to generate a net profit of RMB 38.78 million in its first year of operation, with a projected annual profit increase in subsequent years [14]. - The company has reported that the supplementary working capital project has improved its liquidity and operational capabilities, although specific financial benefits cannot be quantified [14]. Compliance and Reporting - The actual use of funds aligns with previously disclosed information, and there are no discrepancies noted in the reporting of fundraising activities [14].

Core Viewpoint - The report provides a verification of Jiangsu Hanbang Technology Co., Ltd.'s pre-investment of self-raised funds into fundraising projects and payment of issuance expenses, confirming compliance with regulatory requirements [1][4]. Group 1: Verification Report - The verification report is intended solely for Jiangsu Hanbang Technology Co., Ltd. to replace self-raised funds with raised funds for specific projects and expenses [2]. - The management of Hanbang Technology is responsible for providing accurate and complete information in accordance with regulatory guidelines [2]. - The registered accountant's responsibility is to independently verify the information provided by the management [3]. Group 2: Fundraising Overview - Hanbang Technology raised a total of RMB 500.94 million by issuing 22 million shares at RMB 22.77 per share, with net funds amounting to RMB 430.67 million after deducting various fees [5][6]. - The company adjusted the investment amounts for its fundraising projects due to the actual funds raised being lower than initially planned [6]. Group 3: Pre-Investment of Self-Raised Funds - As of May 13, 2025, Hanbang Technology invested RMB 46.43 million of self-raised funds into its fundraising projects, which represents 6.74% of the total investment [7][9]. - The specific projects funded include the construction of a chromatography equipment research center and the production of laboratory chromatography purification instruments [7].

Group 1 - The independent directors of Suzhou Ruikeda Connection Systems Co., Ltd. held a meeting on June 20, 2025, where all three members were present and the meeting complied with relevant laws and regulations [1] - The report on the use of previously raised funds was approved, confirming that the funds were used in accordance with regulations and there were no violations [1] - The report was verified by Yongcheng Accounting Firm, which issued a special verification report on the use of the funds [1] Group 2 - The company prepared a detailed report on non-recurring gains and losses for the periods of Q1 2025, 2024, 2023, and 2022, which accurately reflects the financial situation and complies with relevant laws [2] - Yongcheng Accounting Firm also verified the non-recurring gains and losses report, issuing a verification report for the company [2] - The proposal regarding the non-recurring gains and losses verification report was unanimously approved by the independent directors [2]

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the utilization of the raised funds by Zhejiang Wuzhou New Spring Group Co., Ltd. It includes details on the amounts raised, the allocation of funds, and the changes in investment projects, reflecting the company's compliance with regulatory requirements. Group 1: Fundraising Overview - The company raised a total of RMB 33,000 million through the issuance of 3,300,000 convertible bonds at a face value of RMB 100 each, with a net amount of RMB 31,688.16 million after deducting related expenses [3][4]. - A subsequent non-public offering raised RMB 53,300 million, with a net amount of RMB 53,122.35 million after deducting underwriting and related fees [4][6]. Group 2: Fund Utilization and Changes - As of March 31, 2025, the company had RMB 32,158.75 million from the convertible bonds and RMB 1,676.96 million from the non-public offering in its bank accounts [5][6]. - The company decided to change the investment project from a wind turbine bearing project to a core component development project for line control systems, reflecting a strategic shift in response to market conditions [6][7]. Group 3: Investment Project Performance - The actual investment in the "Intelligent Equipment and Aerospace High-Performance Bearings" project was RMB 30,637.70 million, which is lower than the committed investment of RMB 31,688.16 million, resulting in a difference of RMB 1,050.46 million [8][11]. - The company reported that the actual investment amount completed 75.31% of the committed amount, with ongoing projects progressing as planned [11][12]. Group 4: Temporary Fund Management - The company has utilized idle fundraising for temporary liquidity support, with amounts of RMB 22,000 million and RMB 15,000 million approved for temporary use in different instances, all of which were returned within the stipulated time [15][17]. - As of March 31, 2025, there was an outstanding balance of RMB 11,500 million from the temporary use of idle funds [17]. Group 5: Financial Management - The company has engaged in cash management for idle funds, with approvals for various amounts over time, ensuring that no funds were left in cash management products that had not matured as of March 31, 2025 [20][21].